Last reviewed · How we verify

Candemore Plus Tab — Competitive Intelligence Brief

Candemore Plus Tab (Candemore Plus Tab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Calcium channel blocker combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Candemore Plus Tab (Candemore Plus Tab) — Chong Kun Dang Pharmaceutical. Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Candemore Plus Tab TARGET Candemore Plus Tab Chong Kun Dang Pharmaceutical marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type calcium channel
Olmesartan/amlodipine Olmesartan/amlodipine Institut für Pharmakologie und Präventive Medizin marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel
valsartan/amlodipine valsartan/amlodipine Novartis marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
olmesartan medoxomil and a CCB olmesartan medoxomil and a CCB Daiichi Sankyo Co., Ltd. marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type voltage-gated calcium channel
valsartan/amlodpine valsartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
olmesartan medoxomil / amlodipine or azelnidipine olmesartan medoxomil / amlodipine or azelnidipine COLM Study Research Organization marketed Angiotensin II receptor blocker / Calcium channel blocker combination Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels
Candesartan cilexetil/Amlodipine besylate Candesartan cilexetil/Amlodipine besylate HK inno.N Corporation marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Calcium channel blocker combination class)

  1. Handok Inc. · 3 drugs in this class
  2. Institut für Pharmakologie und Präventive Medizin · 2 drugs in this class
  3. Chong Kun Dang Pharmaceutical · 1 drug in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. HK inno.N Corporation · 1 drug in this class
  6. Novartis · 1 drug in this class
  7. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
  8. University of Pavia · 1 drug in this class
  9. COLM Study Research Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Candemore Plus Tab — Competitive Intelligence Brief. https://druglandscape.com/ci/candemore-plus-tab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: